Neovasculgen

N/A

Report date: 2026/02/13 20:01:31

Base Information

Drug NameNeovasculgen
Drug Alias NameVEGF gene therapy - HSCINeovasculgenPI-VEGF165
ClassificationCell and gene therapy > Gene therapy > Plasmid
Mechanisms of ActionVascular endothelial growth factor A stimulantsAngiogenesis inducers
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsBladder PainDiabetes MellitusFoot Ulcer +[7] 
Global Approved IndicationsPeripheral Arterial Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryRussian Federation
Original Approved Date2011/12/07
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHuman Stem Cells Institute
China Registration ClassN/A

Develop Information

Active CompaniesHuman Stem Cells InstituteJSC NextGen
Inactive CompaniesHuman Stem Cells Institute, Russia
Active IndicationsBladder PainDiabetes MellitusFoot Ulcer +[6] 
Inactive IndicationsPeripheral Nerve Injuries

Other Information

ATC CodeV09G
Related LinksWikipedia